Advertisement

Topics

Fresenius Ends Deal to Buy Akorn, Which Pledges a Fight

20:53 EDT 22 Apr 2018 | Topix

Fresenius SE on Sunday said it is terminating its $4.3 billion agreement to buy generic-drug maker Akorn Inc., but Akorn said it intends to see the deal go through.

Original Article: Fresenius Ends Deal to Buy Akorn, Which Pledges a Fight

NEXT ARTICLE

More From BioPortfolio on "Fresenius Ends Deal to Buy Akorn, Which Pledges a Fight"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...